Vitamin D: The Missing Nutrient Behind the Two Deadly Pandemics, COVID-19 and Cardiovascular Diseases

Abhishek Singh 1, Anusha Chidharla 2, Kriti Agarwal 3, Priyanka Singh 4, 5, Nidhi Jain 6, 7, 8, Gashaw Hassen 9, Salwa Abdelwahed 10, Renu Bhandari 11, 12, Kajal Patel 13, Sachin Gupta 14, Thoyaja Koritala 15, Rizwan Rabbani 16

1. Internal Medicine, Saint Vincent Hospital, Worcester, USA
2. Hematology Oncology, University of Kansas Medical Center, Kansas, USA
3. Department of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, USA
4. Medicine, Smolenks State Medical University, Smolenks, RUS
5. Cardiology, Apex Heart and Vascular Care, New Jersey, USA
6. Medicine and Surgery, Himalayan Institute of Medical Sciences, Dehradun, IND
7. Hematology and Oncology, Brooklyn Cancer Care, Brooklyn, USA
8. Internal Medicine, Sir Ganga Ram Hospital, New Delhi, IND
9. Internal Medicine, Mercy Medical Center, Baltimore, USA
10. Department of Family and Community Medicine, University of Missouri Kansas City School of Medicine, Kansas City, USA
11. Internal Medicine, Manipal College of Medical Sciences, Kaski, NPL
12. Internal Medicine/Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
13. Department of Internal Medicine, Smt. Kashibai Navale Medical College and General Hospital, Nahe, IND
14. Internal Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, USA
15. Internal Medicine, Mayo Clinic, Mankato, USA
16. Nephrology, Temple University Hospital, Philadelphia, USA

Corresponding author: Abhishek Singh, abhishek021196@gmail.com

Abstract

The coronavirus (COVID-19) pandemic is claiming millions of lives and creating an additional burden on health care, which is already affected by the rise of non-communicable diseases (NCDs). The scientific community, on the other side, is enormously engaged with studies to best identify the characteristics of the virus and minimize its effect while supporting the fight to contain NCDs, mainly cardiovascular diseases (CVDs), which are contributing hugely to the global death toll. Hence, the roles of vitamin D in COVID-19 immunity and cardiovascular health are gaining traction recently.

This literature review will mainly focus on summarizing pertinent studies and scientific publications which highlight the association of vitamin D levels with the various outcomes of COVID-19 and CVDs. It will also address how low vitamin D correlates with the epidemiology of CVDs and the immunological mechanisms attributed to COVID-19 severity. We believe that our review may open up hindsight perspectives and further discussions among the physicians in tapping the potential of vitamin D supplementation to tackle the morbidity, mortality, and health care cost of the two deadly diseases, COVID-19 and CVDs.

Introduction And Background

Vitamin D is known for its regulation of calcium levels and for maintaining bone health [1]. However, recent studies suggest that it also has immunomodulatory and anti-inflammatory action. Vitamin D as a strong epigenetic regulator on more than 2500 genes, contributes to its influence on various diseases. Thus, it has an association with serious illnesses like cancers, diabetes mellitus (DM), acute respiratory infections (ARIs), autoimmune diseases like multiple sclerosis, and interestingly cardiovascular diseases (CVDs), the leading cause of death among the non-communicable diseases globally [2-8].

As of February 2022, the total burden of COVID-19 cases in the United States was more than 75.6 million, with mortality exceeding 0.89 million [9]. In the study using the National Health and Nutrition Examination Survey (NHANES) 2011-2012 database, 4962 participants were surveyed and examined in 1981 (39.92%) were found to be vitamin D deficient, which was in concordance with prior data collected in 2005-2006 (also by NHANES) [10]. Certain findings seen in recent studies indicate COVID-19 association with vitamin D status, such as:

Seasonal variation: showing inverse correlations with solar Ultraviolet B (UVB) doses and vitamin D production [11-12]. COVID-19 cases started in winter in the northern hemisphere, and decreased number of cases and death rates were seen in summer, especially in Europe, and increased rates were seen later in July-September in various European countries [13].

Racial disparity: as seen with higher COVID-19 cases and death rates in African Americans and Hispanics...
than European Americans, most likely due to lower vitamin D levels and dark skin [14-16].

While the world is grappling with the COVID-19 outbreak, the pandemic nature of CVDs occurring in parallel is discussed to a lesser extent among the scientific community. Non-communicable diseases (NCDs), mainly CVDs, are killing more people than infectious pandemics accounting for 71% of global mortality [17,18]. CVDs, including coronary heart disease and cerebrovascular disease, are the leading cause of death globally and contributed to 17.9 million deaths in 2019, an estimated 32% of all deaths worldwide [19]. Applying the definition of a pandemic in the sense of a health condition that spans and burdens globally, some literature describes CVDs as ‘the invisible pandemic’, ‘the forgotten pandemic’, ‘the impending global pandemic’, and ‘a pandemic hiding in plain sight’ [20-25].

Vitamin D is not only missing as an important nutrient from those infected by the COVID-19 but also from patients suffering from CVDs, which affect their heart and blood vessels. A recent review by Latic N and Erben RG highlighted the role of vitamin D in cardiovascular health and the association of hypertension, atherosclerosis, and heart failure with vitamin D deficiency which by itself has affected one billion world population [26]. Despite the lack of sound interventional studies which prove the causal relationship between vitamin D supplementation and its beneficial effects on cardiovascular health, most observational and ecological studies strongly support the cardiovascular protective effect of 25(OH) vitamin D [26,27].

Review
Vitamin D deficiency and COVID-19 mortality due to cytokine storm
Cannell et al. in 2015 revealed that vitamin D can lower the production of specific cytokines, including IL-6, in people with inflammatory medical problems [28]. A recent study by McElvaney et al. and two separate reviews by Mahmudpour et al. and Koritala et al. highlighted the presence of a "cytokine storm", which is an out-of-control release of inflammatory cytokine as one of the hallmarks of COVID-19 infection [29-31].

Also, few other studies have demonstrated a higher number of COVID-19-related deaths, particularly in patients with high IL-6 cytokine levels. In the UK, males had 72% higher death rates than females, which, when compared to the study published by Wei et al., showed UK men had 112% higher levels of IL-6 than the mean female levels [32-33]. Similarly, black patients in the UK had death rates 40 percent higher than white patients, aside from the fact that IL-6 levels in black patients were 59 percent higher in the US trial [32,34]. Obese patients died at a rate of 48 percent and higher than non-obese patients in the UK, plus the fact that IL-6 levels in obese patients are 300 times higher than in non-obese patients, according to a US study [32,35]. Although further research is needed to determine the link between vitamin D supplements, IL-6, and COVID-19 endpoints, existing research suggests that vitamin D prescription might be used for its preventative as well as therapeutic role [36].

The interplay between vitamin D and COVID-19 immunity
Vitamin D could play a vital role in reducing the risk, severity, and death from COVID-19 infection through the following possible mechanisms. Regulatory T lymphocytes (Tregs) levels have been reported to be markedly decreased in severe cases. Tregs levels can be increased by supplementing vitamin D [37-38]. Low levels of vitamin D are also associated with an increase in inflammatory cytokines. It has been shown that vitamin D decreases levels of IL-6 and TNF-α [39].

Vitamin D and cardiovascular diseases
Current evidence supports the role of vitamin D in the severity/outcomes of cardiovascular diseases (CVDs), as shown in the studies below. (Table 1)
| Study Author | Study Type | Sample Size | Outcomes Considered | Findings |
|--------------|------------|-------------|---------------------|----------|
| Wang et al. [40] | Meta-analysis of 19 independent studies | 6123 CVD cases among 65994 participants | Incident MI, incident stroke, total CVD mortalities due to CVD, stroke, and coronary heart disease (CHD) | Comparing the lowest to the highest 25(OH)-vitamin D categories, the pooled RR (95% CI) was 1.52 (1.30–1.77) for total CVD, 1.42 (1.19–1.71) for CVD mortality, 1.38 (1.21–1.57) for CHD, and 1.64 (1.27–2.10) for stroke |
| Kim et al. [41] | A cross-sectional study on the prevalence of hypovitaminosis D in adults with CVDs using data from NHANES 2001 to 2004 | 8351 adults | CHD, heart failure (HF), peripheral arterial disease (PAD) | In hypovitaminosis D (<20 ng/ml), adjusted OR (for age, race and gender) was 1.49 with 95% CI [1.17,1.91] for CHD, 2.10 with 95% CI [1.24,3.56] for HF, 1.14 with 95% CI [0.76,1.72] for stroke and 1.82 with 95% CI [1.26,2.61] for PAD |
| Tomaschitz et al. [42] | A cohort study to determine the association between 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxy vitamin D [1,25(OH)2D], and the renin-angiotensin system (RAS) in patients referred for coronary angiography | 3316 subjects | Circulating RAS levels | Age and gender-adjusted analysis of (co) variance (ANCOVA) revealed mean plasma renin concentration (PRC), angiotensin 2 levels, and plasma aldosterone concentration (PAC) values significantly higher in vitamin D deficient patients (25-hydroxyvitamin D < 20 μg/L) in comparison with sufficient vitamin D levels (25-hydroxyvitamin D>30μg/L). (P-value < 0.001 for PRC and angiotensin 2; P-value = 0.045 for PAC). |
| Aleksova et al. [43] | A cross-sectional study on the prevalence of vitamin D deficiency in acute myocardial infarction (AMI) | 478 subjects diagnosed with AMI | AMI | Vitamin D deficiency in 324 (68 %) and insufficiency in 107 (22 %) subjects with AMI. |
| Lee et al. [44] | Prevalence study on subjects enrolled in Translational Research Investigating Underlying Disparities in AMI Patients’ Health Status (TRIUMPH) registry at 24 US hospitals from April 11, 2005, to December 31, 2008 | 239 patients | AMI | The study revealed that at baseline: 179 subjects (75%) were in the deficient range of 25(OH)D levels <20 ng/ml, another 50 subjects had vitamin D levels of 20 to 30 ng/ml, which is in the insufficient range. Resulting in a total of 229 of 239 subjects (96%) in the suboptimal range of 25(OH)D (normal range >30 ng/ml) |
| Belen et al. [45] | A prospective cross-sectional trial was conducted at the Hypertension Outpatient Clinic of Okmeydani Training and Research Hospital, Istanbul, Turkey, from September 2013 to April 2014 | 150 subjects | Resistant Hypertension (RH) | Multivariate regression analysis showed that 25-hydroxyvitamin D levels remained the only independent correlate of RH in the study population (β 0.660, 95% CI 0.572-0.760, p < 0.001). |
| Sun et al. [46] | Prospective case-control study of US female registered nurses aged 30 to 55 years and meta-analysis of six other prospective cohort studies which included both men and women | 464 case-control pairs and additional 1214 stroke cases were included in the meta-analysis | Stroke | Individual Nurses’ health study showed the odds ratio, OR (95% CI), comparing women in the lowest vs. highest tertiles was 1.49 (1.01–2.18; \( P_{\text{trend}}=0.04 \)) after multivariable adjustment. The pooled relative risk of the six prospective studies included in the meta-analysis, RR (95% CI), was 1.52 (1.20–1.85; \( P^2=0.00, P_{\text{heterogeneity}}=0.63 \)) |

**TABLE 1: Role of isolated vitamin D deficiency in CVDs**

It is obvious from the table that various studies were able to reiterate how vitamin D deficiencies and insufficiencies are highly identified in patients with cardiovascular morbidities and mortalities. Patients with low vitamin D are more likely to have higher CVDs like AMI, CHD, HF, PAD, RH, and stroke, in addition to increased circulating RAS levels. Do CVDs play some roles in the severity, morbidity, and mortality of
COVID-19 in patients with hypovitaminosis-D? This important question needs further investigation by others as this review focuses more on Vitamin D’s role in COVID-19.

Vitamin D and acute respiratory infections

The existing experimental data on the effects of vitamin D supplementation on the prevention and treatment of acute respiratory infections (ARIs) in the general population is ambiguous. Furthermore, there is insufficient evidence to conclude the influence of vitamin D supplementation on the severity or length of ARIs, as well as outcomes related to lung damage or ARI-related hospitalization. Vitamin D deficiency (50 nmol/L [20 ng/mL]) and insufficiency (75 nmol/L [30 ng/mL]) are linked to an elevated risk of ARIs, and supplementation for people with deficiency/insufficiency may result in clinically relevant decreases in the frequency of ARIs. Vitamin D supplementation appears to offer a high margin of safety, according to existing experimental evidence, with very few adverse effects reported in children and adults using various dosing techniques [47].

Other studies are questioning the benefit of vitamin D supplementation based on contradictory and inconsistent results. A recent study found that vitamin D in high-dose intermittent bolus, which paradoxically may induce vitamin D inactivating 24-hydroxylase, and fibroblast growth factor 23 failed in preventing rickets [37]. Trials in tuberculosis (TB) and other diseases, as well as meta-analyses of vitamin D supplementation in the prevention of ARIs, indicate the effectiveness of low dosage daily maintenance rather than intermittent bolus doses. Given the well-documented links between COVID-19 risk and vitamin D insufficiency, this is especially important during the present COVID-19 pandemic. We strongly encourage physicians to take notice of these results and to promote the broad use of vitamin D supplementation regularly [48].

Vitamin D supplementation and clinical outcome of COVID-19 patients

The number of deaths during the 1918–1919 ‘Spanish flu’ pandemic was significantly decreased when patients were treated in ‘open-air’ hospitals with access to sunshine, possibly owing to vitamin D’s inhibition of ‘cytokine storm’ [49]. Before effective anti-tubercular therapy, effective TB therapies included cod liver oil, UVB phototherapy, and sunlight, all of which are vitamin D sources [50].

A study done by Alipio M. found that of 212 (100.0%) cases of COVID-19, 49 (23.1%) were identified as mild, 56 (26.4%) were severe, and 48 (22.6%) were critical. The mean serum 25(OH)D level was 25.8 ng/mL. Patients with serum 25(OH)D levels above the mean had mild outcomes, while those below the mean had worst outcomes showing levels of 21.2 ng/mL for severe and 17.1 ng/mL for critical patients. Serum 25(OH)D levels were statistically significant among clinical outcomes (p=0.001). In the same study, 77 (36.3%) cases were identified as vitamin D-deficient, the majority of which were severe (40.3%). In addition, with every standard deviation rise in serum 25(OH)D, the likelihood of having a mild rather than a severe clinical result increased by 7.94 times (OR=0.126, p=0.001). While it’s worth noting that the probabilities of having a mild clinical result rather than a catastrophic outcome were about 19.61 times higher (OR=0.051, p=0.001). More generally, the odds of having a mild clinical outcome increase when serum 25(OH)D level increases [51].

Interestingly, a pilot randomized clinical trial (RCT) published in October 2020 demonstrated that administration of a high dose of Calcifediol (25(OH)D) significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19 [52].

Immunologic mechanisms behind cytokine storm in COVID-19

A study done by Soy et al. found that SARS-CoV-2 cellular entrance is dependent on S proteins on the virion’s surface binding to the cellular ACE2 receptor and S protein priming by TMPRSS2, a host membrane serine protease. After infecting respiratory epithelial cells, SARS-CoV-2 triggers an immunological response that includes the generation of inflammatory cytokines and a modest interferon (IFN) response. The proinflammatory immune responses of pathogenic Th1 cells and intermediate CD14+CD16+monocytes are mediated by membrane-bound immune receptors and downstream signaling pathways. This is followed by macrophage and neutrophil infiltration into the lung tissue, resulting in a cytokine storm [53].

SARS-CoV-2 has the potential to swiftly activate pathogenic Th1 cells, prompting them to generate proinflammatory cytokines such as GM-CSF and interleukin-6 (IL-6). Furthermore, GM-CSF activates CD14+CD16+ inflammatory monocytes, prompting them to produce large levels of IL-6, TNF-α, and other cytokines. Membrane-bound immune receptors (such as Fc and Toll-like receptors) may contribute to an imbalanced inflammatory response, and insufficient IFN-induction may act as a cytokine amplifier. Extracellular nets produced by neutrophils, known as neutrophil extracellular traps, may have a role in cytokine release. The elevated expression of IL-6 and TNF-α in COVID-19 is indicative of a cytokine storm. Hirano and Murakami suggested the angiotensin 2 (AngII) pathway as a possible cause of the cytokine storm [54].

Nuclear factor-κB (NF-κB) is activated by SARS-CoV-2 through pattern-recognition receptors. It binds to ACE2 on the cell surface, causing a decrease in ACE2 expression and an increase in AngII. The AngII-angiotensin
receptor type 1 axis may also generate TNF-α and the soluble form of IL-6Ra (sIL-6Ra) through disintegrin and metalloprotease 17 in addition to activating NF-kB (ADAM17). The IL-6–sIL-6R complex is formed when IL-6 binds to sIL-6R through gp130, and it may activate the signal transducer and activator of transcription 3 (STAT3) in nonimmune cells. Both NF-kB and STAT3 may activate the IL-6 amplifier, resulting in the production of a variety of proinflammatory cytokines and chemokines such as vascular endothelial growth factor (VEGF), monocyte chemoattractant protein 1 (MCP-1), IL-8, and IL-6. IL-6 can not only act in cis-signaling by binding to sIL-6R, but it can also act in trans-signaling by binding to the membrane-bound IL-6 receptor (mIL-6R) through gp130. The latter may cause cytokine storms by having pleiotropic effects on acquired and innate immune cells. SARS-CoV-2 may induce cytokine storms as a result of defective acquired immune responses and uncontrolled inflammatory innate responses [53].

Low vitamin D evident as a risk and predictor of COVID-19 severity

SARS-CoV-2 began to spread around the globe in late 2019, culminating in COVID-19, which has killed a large number of people. Thanks to the results of numerous research, the virus’s genetics, toxicity, and transmission have all been explained. The pulmonary angiotensin-converting enzyme (ACE) 2 was introduced as the viral receptor for entering the cell, similar to the SARS coronavirus. According to an increasing amount of epidemiological and clinical data, vitamin D regulates lung damage via various pathways. The spread and severity of the illness have been related to several clinical signs as well as biological variables. Vitamin D, ACE, and the neutrophil to lymphocyte ratio (NLR) were assessed in COVID-19 patients and compared to a control group in the Mardani et al., 2020 research. In the patients’ group, there were significant changes in vitamin D and ACE levels, as well as NLR. These variables have been shown to have an impact on the prognosis and severity of the illness [55].

In another single-center retrospective cohort analysis, vitamin D insufficiency was related to a greater risk of COVID-19. COVID-19+ individuals with sufficient vitamin D levels exhibited lower blood levels of D-dimer, the inflammatory marker CRP, fewer ground-glass opacities on chest CT images, and shorter hospital stays. According to the results, randomized trials should be performed to determine whether vitamin D levels influence COVID-19 risk. The research was not without flaws. Vitamin D insufficiency may be caused by several chronic illnesses or lifestyle choices, all of which are related to an increased COVID-19 risk. Furthermore, the research only looked at a tiny part of the data in the computerized database at Tokat State Hospital in Turkey [56].

Whilst levels of interleukin-6 (IL-6) are greater in cases of severe COVID-19 infection. This cytokine may play a far larger role in viral infection pathogenesis. Vitamin D is known to regulate IL-6, and its insufficiency is related to worse outcomes. Early COVID-19 mortality data from Italy and the United Kingdom were compared to previously published mean IL-6 levels from these nations, as well as the United States, to see if IL-6 levels before infection might predict the outcome. There was a very significant connection (r = 0.9883; p = 0.00025) between age-stratified death rates and IL-6 levels in previously published data on healthy individuals. To determine whether vitamin D might assist patients to decrease their IL-6 levels, a review of studies investigating the connection between these entities published in 2015 was performed. In eight of the eleven trials, vitamin D was shown to have a substantial decreasing impact on IL-6. Because IL-6 increases viral cell entrance and multiplication, it may be an excellent predictor of death before infection. This supports the use of preventive and therapeutic treatments, such as vitamin D administration, to lower IL-6 levels [57].

A meta-analysis of COVID-19 data from 552 hospitalized patients (189 on vitamin D supplementation and 343 on usual care/placebo) was conducted. Patients who took vitamin D supplements required less time in the ICU (p<0.0001) than patients who did not take vitamin D supplements (OR=0.36; 95% CI: 0.210-0.626). It did, however, contain a lot of heterogeneity, which sensitivity analysis helped to decrease. In terms of mortality, vitamin D supplements are comparable to placebo treatment/standard care (OR=0.93; 95%CI: 0.413-2.113; p=0.87). There was no indication of publication bias in the studies. Subgroup analysis was not feasible due to the limited number of trials; thus, the dosage and duration-dependent impact of vitamin D could not be evaluated. According to the meta-analysis, more solid evidence from RCTs is required to support vitamin D’s impact on mortality, despite the present results suggesting that it may have a role in decreasing COVID-19 severity in hospitalized patients [58].

Conclusions

Suboptimal vitamin D is incriminated as a risk and outcome determinant for other diseases beyond abnormal bone health. Vitamin D is an essential nutrient that has the potential benefit of playing both therapeutic and preventive roles. Its use can be extended to tackle the two deadliest pandemics we are facing now, COVID-19 (communicable) and CVDs (non-communicable). Although more studies are emerging that highlight the epidemiologic, immunologic, and clinical relationship of vitamin D with various diseases, including COVID-19, further research warrants understanding its application and implication in public health intervention.

Additional Information
Disclosures

Conflicts of Interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors would like to acknowledge the efforts of Abhishek Singh: conceptualization, writing - original draft; Anusha Chidhara: resources; Kriti Agarwal: writing - original draft; Priyanka Singh: writing - review & editing; data curation; Nidhi Jain: project administration, writing - original draft; Sachin Gupta: writing - review & editing, writing - original draft; Thoyaja Koritala: conceptualization, supervision, review & editing; Rizwan Rabbani: data curation, writing - review & editing, conceptualization.

References

1. Chibuzor MT, Graham-Kalio D, Osaji JO, Meremikwu MM: Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children. Cochrane Database Syst Rev. 2020, 4:CD012581. 10.1002/14651858.CD012581.pub2
2. Yin K, Agrawal DK: Vitamin D and inflammatory diseases. J Inflamm Res. 2014, 7:69-87. 10.2147/IR.S63898
3. Carlberg C: Vitamin D signaling in the context of innate immunity: focus on human monocytes . Front Immunol. 2019, 10:2211. 10.3389/fimmu.2019.02211
4. Manson JE, Cook NR, Lee IM, et al.: Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019, 380:33-44. 10.1056/NEJMoa1809944
5. Grant WB, AI Anouti F, Moukayed M: Targeted 25-hydroxyvitamin D concentration measurements and vitamin D5 supplementation can have important patient and public health benefits. Eur J Clin Nutr. 2020, 74:566-76. 10.1038/s41430-020-0564-0
6. Pittas AG, Dawson-Hughes B, Sherhan P, et al.: Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019, 381:520-30. 10.1056/NEJMoa1900906
7. Martineau AR, Jolliffe DA, Greenberg L, et al.: Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technol Assess. 2019, 23:1-44. 10.3310/hta23020
8. Hayes CE, Ntabi JM: Multiple sclerosis: lipids, lymphocytes, and vitamin D. Immunometabolism. 2020, 2:10.25900/immunometab2000019
9. Centers for Disease Control and Prevention: COVID data tracker . (2022 ). Accessed: February 4, 2022: https://covid.cdc.gov/covid-data-tracker/#/cases_deathsuper100last7days.
10. Parva NR, Tadepalli S, Singh P, et al.: Prevalence of vitamin D deficiency and associated risk factors in the US population (2011-2012). Cureus. 2018, 10:e2741. 10.7759/cureus.2741
11. Mitri J, Muraro MD, Pittas AG: Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011, 65:1055-15. 10.1038/ejcn.2011.118
12. Kroll MH, Bi C, Garber CC, et al.: Temporal relationship between vitamin D status and parathyroid hormone in the United States. Proc Natl Acad Sci U S A. 2015, 112:18108-13. 10.1073/pnas.1503184112
13. Worldometer: COVID-19 coronavirus pandemic. (2020). Accessed: June 27, 2020: https://www.worldometers.info/coronavirus/.
14. Yancy CW: COVID-19 and African Americans. JAMA. 2020, 323:1891-2. 10.1001/jama.2020.6548
15. Yehia BR, Winegar A, Fogel R, et al.: Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open. 2020, 3:e2018039. 10.1001/jamanetworkopen.2020.18039
16. Ginde AA, Liu MC, Camargo CA Jr: Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009, 169:626-32. 10.1001/archmed.2008.604
17. GBD 2017 Mortality Collaborators: Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1684-735. 10.1016/S0140-6736(18)31981-9
18. Bigua JJ, Nousiap B: The rising burden of non-communicable diseases in sub-Saharan Africa . Lancet Glob Health. 2019, 7:1295-1296. 10.1016/S2214-109X(19)30370-5
19. WHO: Cardiovascular diseases (CVDs) . (2022 ). Accessed: April 7, 2022: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
20. Grennan D: What is a pandemic?. JAMA. 2019, 321:910. 10.1001/jama.2019.0700
21. Chikwore T, Kamiza AB, Oduaran OH, Machipisa T, Fatumo S: Non-communicable diseases pandemic and precision medicine: is Africa ready?. EBioMedicine. 2021, 65:103260. 10.1016/j.ebiom.2021.103260
22. O’Neill Institute for National and Global Health Law: The invisible pandemic of NCDs may now come to light. (April 10, 2020). Accessed: April 7, 2022: https://oneill.law.georgetown.edu/the-invisible-pandemic-of-ncds-may-now-come-to-light/.
23. DuBroff R, Demasi M: Heart disease: the forgotten pandemic . Prev Med. 2021, 153:106791. 10.1016/j.ypmed.2021.106791
24. Chockalingam A, Balaguer-Vintró I, Achutti A, et al.: The World Heart Federation’s white book: impending global pandemic of cardiovascular diseases: challenges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economies in transition. Can J Cardiol. 2008, 24:227-9.
25. Pharmacophorum: Is cardiovascular disease a ‘pandemic hiding in plain sight’? . (June 25, 2021). Accessed: April 7, 2022: https://pharmacophorum.com/views-and-analysis/is-cardiovascular-disease-a-pandemic-hiding-in-plain-sight/.

26. Latic N, Erbers RG: Vitamin D and cardiovascular disease, with emphasis on hypertension, atherosclerosis, and heart failure. Int J Mol Sci. 2020, 21:10.3390/ijms21186483

27. Wimalawansa SJ: Vitamin D and cardiovascular diseases: causality . J Steroid Biochem Mol Biol. 2018, 175:29-43. 10.1016/j.jsbmb.2016.12.016

28. Cannell JJ, Grant WB, Holick MF: Vitamin D and inflammation. Dermatoendocrinol. 2014, 6:e983401. 10.4161/derm.2014.983401

29. McElvaney OJ, McEvoy NL, McElvaney OF, et al.: Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020, 202:812-21. 10.1164/rccm.202005-1583OC

30. Mahmudpour M, Roodzehi J, Keshavarz M, Farrokhii S, Nabiipour I: COVID-19 cytokine storm: the anger of cytokine inflammation. Cytokine. 2020, 133:151511. 10.1016/j.cyto.2020.151511

31. Koritala T, Pattan V, Tirupathi R, et al.: Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: a narrative review. Infez Med. 2021, 29:495-505. 10.53854/imm-2904-1

32. Williamson EJ, Walker AJ, Bhaskaran K, et al.: Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020, 584:450-6. 10.1038/s41586-020-2521-4

33. Wei J, Xu H, Davies IL, et al.: Increase of plasma IL-6 concentration with age in healthy subjects . Life Sci. 1992, 51:1953-1956. 10.1016/0024-3205(92)90112-3

34. Stowe RP, Peek MK, Cutchin MP, Goodwin JS: Plasma cytokine levels in a population-based study: relation to age and ethnicity . J Gerontol A Biol Sci Med Sci. 2010, 65:429-33. 10.1093/gerona/glp198

35. Khaodhiar L, Ling PR, Blackburn GL, Blijstrian BR: Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. J Parenter Enteral Nutr. 2004, 28:410-5. 10.1173/pent.28.5.410

36. Silberstein M: Vitamin D: a simpler alternative to tocilizumab for trial in COVID-19? Med Hypotheses. 2020, 140:109767. 10.1016/j.mehy.2020.109767

37. Chen G, Wu D, Gao W, et al.: Clinical and immunological features of severe and moderate coronavirus disease 2019 . Clin Invest. 2020, 130:2620-9. 10.1177/1355816720912887

38. Fisher SA, Rahimzadeh M, Brierley C, et al.: The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: a systematic review. PLoS One. 2019, 14:e0222513. 10.1371/journal.pone.0222513

39. Alhassan Mohammed H, Mirehafiyeh A, Vahedi H, Hemmazi G, Mousavi Nasi Khameneh A, Parastouei K, Saboor-Yaraghi AA: Vitamin D and inflammation . Dermatoendocrinol. 2014, 6:e983401. 10.53854/liim-2904-1

40. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ: Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008, 102:1540-4. 10.1016/j.amjcard.2008.06.067

41. Tomsachitza A, Pilz S, Ritz E, Grammer T, Boehm BO, März W: Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafener Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta. 2010, 411:1534-60. 10.1016/j.cca.2010.05.037

42. Alekssova A, Belfiore R, Carriere C, Kassem S, La Carrubba S, Barbati G, Sinagra G: The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: a systematic review. PLoS One. 2019, 14:e0222513. 10.1371/journal.pone.0222513

43. Lee JH, Gadi R, Spertus JA, Tang F, O’Keefe JH: Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study . J Steroid Biochem Mol Biol. 2020, 202:105751. 10.1016/j.jsbmb.2020.105751

44. Soy M, Keser G, Atagündüz I, Tahak F, Atagündüz I, Kayhan S: Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020, 39:2085-94. 10.1007/s10067-020-05190-5

45. Hirano T, Murakami M: COVID-19: a new virus, but a familiar receptor and cytokine release syndrome . Immunity. 2020, 52:731-3. 10.1016/j.immuni.2020.04.003
55. Mardani R, Alamdary A, Mousavi Nasab SD, Gholami R, Ahnadi N, Gholami A: Association of vitamin D with the modulation of the disease severity in COVID-19. Virus Res. 2020, 289:198148. 10.1016/j.virusres.2020.198148

56. Demir M, Demir F, Aygun H: Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease. J Med Virol. 2021, 93:2992-9. 10.1002/jmv.26832

57. Silberstein M: Correlation between premorbid IL-6 levels and COVID-19 mortality: potential role for vitamin D. Int Immunopharmacol. 2020, 88:106995. 10.1016/j.intimp.2020.106995

58. Shah K, Saxena D, Mavalankar D: Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis. QJM. 2021, 114:175-81. 10.1093/qjmed/hcab009